Dipeptidyl peptidase-4 (DPP-4) inhibitors offer novel opportunities for the management of T2DM as they are endowed with a new mechanism of action, potentiating the physiological function of endogenous incretin, glucagon-like peptide 1 (GLP-1). The gene discussed is DPP4; the disease is type 2 diabetes mellitus.